Primary Four Repeat Tauopathies (4RT) clinical trials at UCSF
1 in progress, 0 open to new patients
Sorry, in progress, not accepting new patients
The purpose of this study is to determine the safety and tolerability [maximum tolerated dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT), corticobasal syndrome (CBS; also called corticobasal degeneration, CBD) or progressive supranuclear palsy (PSP).
San Francisco, California and other locations